Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257943 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%
A Phase 1 study of Lice; Head Lice, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 413
- Enrollment target
- 1
- Study location
NCT03257943: Completed Phase 1 study of Lice; Head Lice, sponsored by Sun Pharmaceutical Industries.
NCT03257943 is a Phase 1 study of Lice; Head Lice that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 413 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (588% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03257943, a Phase 1 study of Lice; Head Lice, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 413 participants
- Enrollment target
- 1
- Study location
Study Summary
A Multi-Center, Double-Blind, Randomized, Placebo controlled, Parallel-group study, comparing Ivermectin Lotion, 0.5%
Primary Outcome
Demonstration of Bioequivalence in proportion of index subjects who are lice free
Conditions Studied
Interventions
- DRUG Ivermectin Lotion, 0.5%
- DRUG SKLICE (ivermectin) Lotion, 0.5%
- DRUG Vehicle of the Test product
Study Locations (1)
New York
- Taro Pharmaceuticals USA Inc. - Hawthorne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2017-08-18 |
| Phase | Phase 1 |
What the finished NCT03257943 record still lists
NCT03257943 is an interventional study that assigns participants to a tested intervention. The registered 413 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (588% higher).
The record links to 1 condition, with Lice; Head Lice appearing as the primary indexed condition, and to 3 interventions - of which Ivermectin Lotion, 0.5% is the first listed.
NCT03257943 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03257943 about?
NCT03257943 is a clinical study titled "A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%". A Multi-Center, Double-Blind, Randomized, Placebo controlled, Parallel-group study, comparing Ivermectin Lotion, 0.5%
What is the current status of trial NCT03257943?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 413 participants. The study started on 2017-03-20. Estimated completion is 2017-08-18.
What conditions does trial NCT03257943 study?
This clinical trial studies the following conditions: Lice; Head Lice.
What interventions are being tested in trial NCT03257943?
The interventions under investigation include: Ivermectin Lotion, 0.5% (DRUG), SKLICE (ivermectin) Lotion, 0.5% (DRUG), Vehicle of the Test product (DRUG).
Who is sponsoring clinical trial NCT03257943?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03257943 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03257943's enrollment target sits among peer trials
413 72nd of 2000 higher than 1,928 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- NCT06697197 · 413 participants · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
- NCT04776941 · 414 participants · NA
Expressive Writing for the Management of Stress in Cancer Survivors
- NCT06792552 · 414 participants · Phase 1
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI